SCHEMBL24148142

SCHEMBL24148142

FCCn1ncc2ccc(Br)cc21

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMO O15229 6/20 0.64
HTR2A P28223 4/20 0.50
HTR2C P28335 4/20 0.50
HTR2B P41595 3/20 0.50
FGFR1 P11362 1/20 0.43
FGFR4 P22455 1/20 0.43
EGFR P00533 2/20 0.39
IRAK4 Q9NWZ3 2/20 0.38
CYP1A2 P05177 1/20 0.37
HTR1A P08908 2/20 0.37
ADRA2A P08913 2/20 0.37
ADRA2B P18089 2/20 0.37
ADRA2C P18825 2/20 0.37
HTR1D P28221 1/20 0.37
HTR7 P34969 1/20 0.37
HTR4 Q13639 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21183580 0.87 KMO (0.49) KMOHTR2AHTR2CHTR2BEGFR
SCHEMBL17673818 0.85 KMO (0.66) KMOHTR2AHTR2CHTR2BFGFR1
SCHEMBL7253033 0.83 KMO (0.68) KMOHTR2AHTR2CHTR2BFGFR1
SCHEMBL23994369 0.83 KMO (0.59) KMOHTR2AHTR2CHTR2BFGFR1
SCHEMBL17673897 0.82 KMO (0.62) KMOHTR2AHTR2CHTR2BFGFR1
SCHEMBL30817517 0.81 KMO (0.60) KMOHTR2AHTR2CHTR2BFGFR1
SCHEMBL19703376 0.80 KMO (0.64) KMOHTR2AHTR2CHTR2BCYP1A2
SCHEMBL14910829 0.80 HTR2A (0.54) KMOHTR2AHTR2CHTR2BCYP1A2
SCHEMBL17678345 0.80 KMO (0.59) KMOHTR2AHTR2CHTR2BFGFR1
SCHEMBL7253603 0.80 KMO (0.59) KMOHTR2AHTR2CHTR2BFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 US disclosed
US-20230056253-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-23 US disclosed
WO-2021262684-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056253-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS KMO 4429/4885HTR2A 4210/4885HTR2C 4296/4885
US-11731953-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS KMO 4429/4885HTR2A 4210/4885HTR2C 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.